100% Tariff on Generics to Squeeze Supply: 3-5 Year Reshoring Gap Leaves U.S. Vulnerable

For supply chain and logistics professionals, the generic drug tariff timeline presents an immediate strategic dilemma. With a two-year duty-free window starting August 1, 2026, companies must decide whether to accept margin erosion, exit products, or invest in domestic manufacturing that won’t come online until at least 2029–2031. Given that APIs still come from China and India, reshoring final dosage alone may not mitigate tariff impact. This article maps the supply risks.

On July 21, 2026, President Trump announced that imported generic drugs will remain duty-free for two full years—until July 31, 2028—then face a 100% tariff beginning August 1, 2028, escalating to 200% from August 1, 2029. This move, grounded in Section 232 of the Trade Expansion Act, closes the exemption granted in the April 2, 2026 executive order that imposed 100% levies on patented medicines but explicitly excluded generics, biosimilars, and their active pharmaceutical ingredients (APIs). With that exclusion now carrying an expiry date, the entire generic drug market faces a dramatic disruption.

“

On July 21, 2026, President Trump announced that imported generic drugs will remain duty-free for two full years—until July 31, 2028—then face a 100% tariff beginning August 1, 2028, escalating to 200% from August 1, 2029.

The core issue is one of economics, not politics. Generic drugs account for roughly nine out of every ten U.S. prescriptions, yet they represent only a small fraction of total drug spending. Two decades of fierce price competition, combined with the purchasing power of three dominant buying groups, have pushed the cost of common tablets to mere pennies apiece. At those price points, a 100% duty transforms a thin profit into a certain loss. Crucially, the usual market mechanism of passing costs to consumers is blocked: Medicaid inflation‑based rebates penalize price increases, the 340B program mandates deep discounts for safety‑net hospitals, and multi‑year supply contracts lock in pricing. The rational response for many manufacturers will therefore be product discontinuation, not reshoring or price adjustments. The first-order effect will be a shrinkage in the variety and availability of generic medicines, not a spike in their sticker prices.

The timeline offers little respite. Although two years of duty‑free status may seem generous, the construction of a new tablet manufacturing plant—from groundbreaking to FDA‑approved commercial supply—requires three to five years, and injectable facilities take even longer. Even if final dosage production could eventually be repatriated, the active ingredients would still be sourced predominantly from China and India, which are themselves subject to ongoing trade tensions. The policy thus risks dismantling the existing supply chain without providing a workable domestic alternative, setting the stage for drug shortages in the very segment that forms the backbone of American healthcare.